Category: Cardiovascular Systems Inc.Syndicate content

Cardiovascular Systems launches COAST heart disease study

June 12, 2014 by Arezu Sarvestani

Cardiovascular Systems begins enrollment in its COAST trial, evaluating the micro crown Orbital Atherectomy System in patients with hard-to-treat coronary artery disease.

Cardiovascular Systems launches COAST heart disease study

Boston Scientific's peripherals buy bad news for Cardiovascular Systems? | Medtech Wall Street news for the week of May 19, 2014

May 22, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Is Boston Scientific's peripherals buy bad news for Cardiovascular Systems?; M&A: Medtech makers use acquisitions to fill niches; Report: Deals in the medical device sector rose 200% in Q1; CareFusion plans $1B debt offering; Activist investor Oracle revives proxy war at Biolase.

Is Boston Scientific's peripherals buy bad news for Cardiovascular Systems?

May 15, 2014 by Arezu Sarvestani

Is Boston Scientific's peripherals buy bad news for Cardiovascular Systems?

MDT owes $15.4 million to bone cement maker Pabban Development | Medtech legal news for the week of May 19, 2014

May 19, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Jury: Medtronic owes bone cement acquisition $15M; North Carolina DA probes Cardiovascular Devices; Negligence claims stand in Medtronic Infuse lawsuits; Judge slaps sanction on J&J's lawyers in Ethicon pelvic mesh case; Stryker must face class action employment claims.

Jury: Medtronic owes bone cement acquisition $15M

May 12, 2014 by Brad Perriello

Jury: Medtronic owes bone cement acquisition $15M

Is Boston Scientific's peripherals buy bad news for Cardiovascular Systems?

May 15, 2014 by Arezu Sarvestani

Cardiovascular Systems' shares drop as Boston Scientific positions itself as a peripherals market rival with the $415 million acquisition of Bayer AG's interventional business.

Is Boston Scientific's peripherals buy bad news for Cardiovascular Systems?

Boston Scientific's (NYSE:BSX) $415 million acquisition of Bayer AG's interventional unit is a strong move for the company, but it may bode ill for other peripheral players.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

North Carolina DA probes Cardiovascular Devices

May 12, 2014 by Brad Perriello

The district attorney for western North Carolina investigates Cardiovascular Systems for possible violations of the False Claims Act.

YYmeta

Cardiovascular Systems (NSDQ:CSII) late last week became the latest medical device company to reveal a federal probe into possible marketing or False Claims Act violations.

Cardiovascular Systems jumps as sales increase 32%

May 1, 2014 by Arezu Sarvestani

Planned investments take a big chunk out of Cardiovascular Systems' bottom line, but a 32% boost in sales prompts some Wall Street love.

Cardiovascular Systems gains as sales, losses soar

Cardiovascular Systems' (NSDQ:CSII) revenues soared in its 3rd quarter, driven primarily by the popularity of the company's Stealth 360 device, a peripheral artery disease treatment system.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp